Sarah-Louise Gillespie

Dr. Sarah-Louise Gillespie

Royal Infirmary of Edinburgh
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 January 2023 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
SGSarah-Louise Gillespie
Sarah-Louise Gillespie
THTim Hanrahan
Tim Hanrahan
DRDon C. Rockey
Don C. Rockey
AMAvik Majumdar
Avik Majumdar
PHPeter C. Hayes
Peter C. Hayes

16 February 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SGSarah-Louise Gillespie
Sarah-Louise Gillespie
NMNorma C. McAvoy
Norma C. McAvoy
DYDiana E. Yung
Diana E. Yung
ARAlexander Robertson
Alexander Robertson
John PlevrisJohn Plevris
John Plevris
PHPeter C. Hayes
Peter C. Hayes
Variceal haemorrhage is a severe complication of liver disease with high mortality. Human recombinant thrombin has gained popularity in the management of variceal haemorrhage. We report on the use of thrombin for gastric and ectopic varices at a regional tertiary care centre. This was a retrospective observational study. Patients with portal hypertension who received endoscopic injection of recombinant thrombin were identified and data collected on haemostasis and rebleeding rates, complications and mortality. Patients were grouped by indication for thrombin injection: gastric/oesophageal/ectopic varices and endoscopic band ligation (EBL)-induced ulceration. 155 patients (96M/59F, mean age 58.3 years) received endoscopic thrombin injection. Mean volume of thrombin injected at index endoscopy was 9.5 ml/2375IU. Initial haemostasis was achieved in 144 patients (92.9%). Rebleeding occurred in a total of 53 patients (36.8%) divided as follows: early rebleeding ( 30 days)—11 patients (7.6%). There was statistically significant difference in rate of initial haemostasis between Child-Pugh A/B patients vs Child-Pugh C (p = 0.046). There was no significant difference in rebleeding rates between different indication groups (p = 0.78), by presence of cirrhosis or by Child-Pugh Score. All-cause mortality at 6 weeks was 18.7%; 1-year mortality 37.4% (median follow-up 48 months). There was no significant difference in mortality between groups (p = 0.37). No significant adverse events or complications were reported. Thrombin is effective and safe for gastric varices and other portal-hypertension-related bleeding including oesophageal varices, ulcers secondary to EBL and ectopic varices.

20 May 2025 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
RSR. Sinha
R. Sinha
SGSarah-Louise Gillespie
Sarah-Louise Gillespie
PBP. Brinkman
P. Brinkman
PBP. Bassett
P. Bassett
KLK. A. Lockman
K. A. Lockman
JPJ. N. Plevris
J. N. Plevris

11 August 2021 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
SGSarah-Louise Gillespie
Sarah-Louise Gillespie
PHPeter C. Hayes
Peter C. Hayes
This article is linked to Wijarnpreecha et al papers. To view these articles, visit https://doi.org/10.1111/apt.16490 and https://doi.org/10.1111/apt.16526